Stock Alert: GenMark Diagnostics

(RTTNews) - Shares of GenMark Diagnostics Inc. (GNMK) are soaring 90% in pre-market today, extending a 16% gain in the previous session. The stock has been trading between $3.36 and $8.17 in the past one year, and closed Thursday's trade at $4.13, up 57 cents or 16.01%.

The company, on March 19, announced that the U.S. Food and Drug Administration or FDA has issued Emergency Use Authorization or EUA for GenMark's ePlex SARS-CoV-2 Test.

GenMark's test was developed for the qualitative detection of SARS-CoV-2 virus in nasopharyngeal swab samples for patients suspected of COVID-19 by their health care provider.

Further, GenMark continues to invest in additional manufacturing capacity with current capability to supply about 100,000 ePlex tests per month to support near patient testing.

GNMK is currently trading at $7.83, up $3.70 or 89.59% in the pre-market trading session.